Company intelligence / Profile preview

SineuGene Therapeutics

Ownership: Private
Development stage: Preclinical

Overview

SNUG01, an AAV gene therapy drug for ALS, has completed first subject administration in clinical study at Peking University Third Hospital. The first subject has reached 3 weeks post-administration with stable condition and no serious adverse events observed as of reporting[5].

Therapeutic areas: Neurology
Modalities: AAV-based gene therapyAntisense Oligonucleotides (ASO)
Industry: Biotech

Drug pipeline

1 asset

SG001

Preclinical

Partnerships

Peking University Third Hospital (for clinical trials)

Beyond the preview

Go deeper on SineuGene Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SineuGene Therapeutics.

Explore the full profile